Social Media Ideas for Abbvie

<![CDATA[AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal]]>

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sal...

<![CDATA[Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion]]>

AbbVie to Acquire Apogee Therapeutics for $10.9B

Apogee’s lead candidate zumilokibart, an IL-13 inhibitor also called APG777, is a long-acting treatment that, according to the company, holds “pipeline-in-a-product potential” beca...

Is AbbVie a Buy After Its Purchase of Apogee?

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly...

AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge

Apogee Therapeutics brings AbbVie a long-acting antibody ready for Phase 3 testing in atopic dermatitis, also called eczema. This therapy’s pipeline in a product potential includes...

AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

AbbVie Oncology

AbbVie Oncology Anonymous (not verified) Fri, 07/03/2026 - 06:06 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...

Dividend Kings In Focus: AbbVie

Updated on July 9th, 2026 by Josh Arnold We believe that long-term investors should focus on the highest-quality dividend-growth stocks. These are companies with long histories of...

Two Paths to Growth: Johnson & Johnson vs AbbVie

AbbVie Oncology

AbbVie Oncology Anonymous (not verified) Fri, 07/10/2026 - 09:11 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...

AbbVie's Skyrizi gains pediatric psoriatic disease indication

AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer

AbbVie drug Decnupaz received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This antibody drug conjugate came from AbbVie’s 2023 ImmunoGen acqui...

<![CDATA[Eli Lilly and Abbisko Announce Drug Development Collaboration]]>

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration]]>

ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis - S...

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its...

StockWatch: New UC Data Sparks Smoother Sailing for Abivax

Less than a month after its stock roller-coastered on safety signals associated with its late-stage ulcerative colitis (UC) drug candidate obefazimod, shares of Abivax (Euronext Pa...

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?

In the past five years, this top healthcare stock has risen by close to 130%.

MSLs at Abbvie

MSLs at Abbvie Anonymous (not verified) Thu, 06/11/2026 - 20:51 field_thread_url https://cafepharma.com/boards/threads/msls-at-abbvie.668170/...

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years